Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Erratum for Huguet et al., J Clin Oncol 27 (6) 911-918.

Journal of Clinical Oncology, Vol 27, No 15 (May 20), 2009: pp. 2574
© 2009 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2009.23.1985

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ERRATUM

The February 20, 2009, article by Huguet et al, entitled, "Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study" (J Clin Oncol 27:911–918, 2009), contained errors in Table 1.

Under "Remission induction," the term "corticosteroid prophase" was given, whereas it should have been "corticosteroid prephase." The dose for L-asparaginase was given as, "6,000 U/m2/d on days 8, 10, 12, 18, 20, 22, 24, and 26," and it should have been, "6,000 U/m2/d on days 8, 10, 12, 20, 22, 24, 26, and 28." Also, the dose for cyclophosphamide (CPM) was given as, "750 mg/m2/d on days 1 and 8; 750 mg/m2 on day 15 in good early responders; 500 mg/m2/12 h on days 15 and 16 in poor early responders," and should have been, "750 mg/m2/d on day 1; 750 mg/m2/d on day 15 in good early responders; 500 mg/m2/12 h on days 15 and 16 in poor early responders."

Under "Consolidation blocks 3, 6, and 9," the dose for CPM was given as, "500 mg/m2 on days 29 and 30," and should have been, "500 mg/m2/d on days 29 and 30." Also, the dose for VP-16 was given as, "75 mg/m2m/d on days 29 and 30," and should have been "75 mg/m2/d on days 29 and 30."

Under "Late intensification (between consolidation blocks 6 and 7)," the dose for lenograstim was not indicated for patients in complete remission after the first induction course, and should have been, "150 µg/m2/d if neutrophils < 0.5 G/L to myeloid recovery."

Under "Maintenance therapy," the dose for prednisone (PDN) was given as, "40 mg/m2/d on days 1-14 monthly for 12 months," and should have been, "40 mg/m2/d on days 1-7 monthly for 12 months."

Under "CNS therapy, Treatment of patients with initial CNS involvement," the dose for triple IT injects was given as, "Eight between days 7 and 21 of induction; four during the first two consolidation blocks; one at day 29 of consolidation blocks 3 and 6," and should have been, "Eight between days -7 and 21 of induction; four during the first two consolidation blocks; one at day 29 of consolidation blocks 3 and 6." Also, the dose for cranial irradiation was given as, "15 Gy before SCT or 18 Gy before late intensification; 6-MP 60 mg/m2/d during irradiation," and should have been, "15 Gy before SCT or 24 Gy before maintenance therapy initiation; 6-MP 60 mg/m2/d during irradiation."

Also under "CNS therapy," the footnote for triple IT injections was given as:

{dagger}Triple IT injections consisted of MTX 15 mg, Ara-C 40 mg, and PDN 40 mg.

While it should have been:

{dagger}Triple IT injections consisted of MTX 15 mg, Ara-C 40 mg, and methylprednisolone 40 mg.

The online version has been corrected in departure from the print.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online